GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Shiller PE Ratio

Citius Pharmaceuticals (Citius Pharmaceuticals) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Citius Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Citius Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Shiller PE Ratio Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Citius Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Citius Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Citius Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's Shiller PE Ratio falls into.



Citius Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Citius Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Citius Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.05/131.7762*131.7762
=-0.050

Current CPI (Mar. 2024) = 131.7762.

Citius Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.029 100.560 -0.038
201409 0.000 100.428 0.000
201412 -0.450 99.070 -0.599
201503 -0.150 99.621 -0.198
201506 -0.450 100.684 -0.589
201509 -0.470 100.392 -0.617
201512 -0.600 99.792 -0.792
201603 -0.300 100.470 -0.393
201606 -0.750 101.688 -0.972
201609 -0.510 101.861 -0.660
201612 -0.440 101.863 -0.569
201703 -0.550 102.862 -0.705
201706 -0.480 103.349 -0.612
201709 -0.420 104.136 -0.531
201712 -0.380 104.011 -0.481
201803 -0.440 105.290 -0.551
201806 -0.190 106.317 -0.235
201809 -0.180 106.507 -0.223
201812 -0.220 105.998 -0.274
201903 -0.200 107.251 -0.246
201906 -0.200 108.070 -0.244
201909 -0.160 108.329 -0.195
201912 -0.150 108.420 -0.182
202003 -0.130 108.902 -0.157
202006 -0.110 108.767 -0.133
202009 -0.070 109.815 -0.084
202012 -0.150 109.897 -0.180
202103 -0.040 111.754 -0.047
202106 -0.050 114.631 -0.057
202109 -0.030 115.734 -0.034
202112 -0.060 117.630 -0.067
202203 -0.050 121.301 -0.054
202206 -0.060 125.017 -0.063
202209 -0.050 125.227 -0.053
202212 -0.020 125.222 -0.021
202303 -0.070 127.348 -0.072
202306 -0.060 128.729 -0.061
202309 -0.070 129.860 -0.071
202312 -0.060 129.419 -0.061
202403 -0.050 131.776 -0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Citius Pharmaceuticals  (NAS:CTXR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Citius Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016

Citius Pharmaceuticals (Citius Pharmaceuticals) Headlines

From GuruFocus